Christopher A. D'Avella, MD
Hematology, Medical Oncology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Penn Presbyterian
Penn Medicine Provider

About me

  • Section Chief, Hematology/Oncology, Penn Presbyterian Medical Center
  • Co-Director, Cancer Diagnostics Clinic
  • Assistant Professor of Clinical Medicine (Hematology-Oncology)

Education and training

  • Medical School: George Washington University
  • Residency: University of Pittsburgh Medical Center
  • Fellowship: Temple University Hospital

What my patients think about me

Average Rating

249 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

October 2025
very attentive
October 2025
very patient with the patients
October 2025
dr. d'avella is caring while providing necessary support, guidance and information
October 2025
i receive good help

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. D'Avella is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Shannon Ugarte, Christopher D'Avella, Alec Kacew, Peter Gabriel, Christine A. Ciunci, Megan Roy, Amy Schwartz, Melissa Koepke, Katie Boyk, Suzanne Walker, Jessica Tindall, Megan Mashburn, David W. Dougherty Evaluating the impact of the cancer diagnostic clinic: A two-year update on timely access, diagnosis, and treatment. , American Society of Clinical Oncology Quality Care Symposium Annual Meeting, Boston, MA.: 2025


Christopher D'Avella Inside the Boom of Urgent Care: How It’s Changing American Medicine , Interview for National Public Radio Broadcast WHYY: 2025


Jacob B. Reibel, Christopher D'Avella, Igor Makhlin, Mengru Wang, Maneet Kaur, Yunzhi Qian, Rebecca L. Maniago, Ivy Altomare, Lawrence N. Shulman Guideline concordant osimertinib and durvalumab in two US non-small cell lung cancer cohorts. , American Society of Clinical Oncology Quality Care Symposium, Boston, MA: 2025


Christopher D'Avella, Meredith Doherty, E. Paul Wileyto, Jason Ma, Suzanne Walker, Jessica Jacoby, Chelsea Brown, Chiu Yi Tan, Tamara Cadet Financial toxicity screening in an urban underserved patient population with cancer , American Society of Clinical Oncology Quality Symposium, San Fransisco, CA.: 2024


Shannon Ugarte, Christopher D'Avella, Peter Edward Gabriel, Christine Agnes Ciunci, Megan Roy, Amy Schwartz, Katie Boyk, Suzanne Walker, Jessica Tindall, and David W. Dougherty The cancer diagnostic clinic: A rapid access clinic to improve outcomes for patients with a suspected cancer diagnosis , American Society of Clinical Oncology Quality Care Symposium Meeting, San Francisco, CA.: 2024


Sun L, Cohen RB, D'Avella CA, Singh AP, Schoenfeld JD, Hanna GJ. Overall Survival, Treatment Duration, and Rechallenge Outcomes With ICI Therapy for Recurrent or Metastatic HNSCC , JAMA Netw Open, 7(8): 2024,e2428526


Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N. Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation , Clin Lung Cancer, 25(3): 2024,e161-e171.


Meredith Doherty, Kellie Bresz, Kimberly Guglielmo, Christopher Davella, Tamara Cadet, Suzanne Walker, Paul Wileyto Does financial advocacy improve appointment keeping in patients receiving chemotherapy? , American Society of Clinical Oncology Quality Care Symposium, Boston, MA.: 2023


Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression , Clin Lung Cancer, 17(23): 2023,S1525-7304


Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME. Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens , Clin Lung Cancer, 24(6): 2023,558-562.e2.